Here's how Thomas Nilsson writes in his latest analysis of CombiGene:
 As the company's epilepsy project CG01 enters phase 1/2 studies in 2022, we have recently raised the probability of launch to 15%. As the company enters a more intensive development phase, we have adjusted our cost estimates for 2021 and 2022. We adjust our target price to SEK 21 after the reverse split the company has carried out that reduced the number of outstanding shares to 19.8 million. Our previous target price of SEK 1,5 was based on 229,3 million outstanding shares.

The analysis is only available in Swedish

Läs hela analysen här »

Attachments

  • Original document
  • Permalink

Disclaimer

Combigene AB published this content on 07 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2021 13:01:07 UTC.